Amylin inks diabetes pact with Biocon

San Diego-based Amylin Pharmaceuticals plans to join forces with India's Biocon to develop a new therapy for diabetes. The deal combines Amylin's expertise with hybrid molecules with Biocon's prowess in manufacturing and development. The deal can "unleash the potential of cutting-edge peptide science to transform the lives of patients with diabetes," says Amylin CEO Dan Bradbury. Report